For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  PRL-8-53
Cognitiveanecdotal

PRL-8-53

Methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate
Cognitive
ASK VERA ABOUT THIS ↗BROWSE THE CATALOG ↗
Category
Cognitive
Evidence grade
E
PubMed records
1
Female-tagged
0
Sex-analysis
0
CAS
—
E
Evidence grade E, Only anecdotal or in-vitro reports found across 1 indexed sources. How grades work →
Female evidence: None
PRL-8-53: of 1 PubMed record, 0 are tagged as including female subjects and 0 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

PRL-8-53 is a synthetic benzoate compound that appeared in early cognition research as a candidate for studying memory consolidation. It is one of the older entries in the nootropic research literature, with most of its characterization dating to a limited number of early studies.

In those research models, PRL-8-53 has been studied for its association with cholinergic and dopaminergic signaling relevant to learning and memory tasks. Because the indexed literature is small, it functions in a catalog mostly as a historical and mechanistic reference point rather than a heavily replicated material.

That thin evidence base is the honest framing: PRL-8-53 is a compound where research interest has outpaced the published record. Whether any of its studied mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.

Summary

PRL-8-53 is a synthetic compound known almost entirely from a single 1978 human study reporting improved word retention. That result has not been independently replicated in the indexed literature, so its evidence, including any female-specific effect, is effectively a single unconfirmed report.

Evidence in women

Menstrual cycle
Unstudied
The single study did not examine menstrual cycle effects.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data exist.
Hormonal interactions
Unstudied
No data on hormonal interactions.
Perimenopause & menopause
Unstudied
No perimenopausal or menopausal data.
Sex differences
Unstudied
The lone 1978 study did not report sex-stratified outcomes.

Mechanism

Proposed to modulate cholinergic and dopaminergic transmission; its mechanism in humans is not well characterized.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Low oral doses were used in the single 1978 study; no established or validated dose.
Routesoral
Female-specific dosingNot established

Contraindications: insufficient data to characterize

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

insufficient data to characterize (essentially one small human study)

PRL-8-53 reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for PRL-8-53

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from PRL-8-53's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is PRL-8-53?

PRL-8-53, also known as Methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate, is a research compound in our cognitive category. PRL-8-53 is a synthetic compound known almost entirely from a single 1978 human study reporting improved word retention.

Is PRL-8-53 studied in women?

PRL-8-53: of 1 PubMed record, 0 are tagged as including female subjects and 0 carry a sex-analysis tag. We grade this none: no PubMed record for PRL-8-53 is tagged as including female subjects, so its effects in women are effectively unstudied. That blank is the finding, not a safety signal, and we do not fill it with guesses.

Has PRL-8-53 been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data exist. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does PRL-8-53 have, and why?

PRL-8-53 carries evidence grade E. Only anecdotal or in-vitro reports found across 1 indexed sources.. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for PRL-8-53?

No. A female-specific dose for PRL-8-53 is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is PRL-8-53 administered in research?

In the published literature, PRL-8-53 is administered via oral. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for PRL-8-53?

Effects reported in the research literature include insufficient data to characterize (essentially one small human study). Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

How should PRL-8-53 be stored and handled?

PRL-8-53 sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy PRL-8-53 for research?

PRL-8-53 is not currently listed by our research-use partner, Aurevena Research, but their catalog carries related compounds. Code research15 applies 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Browse the Aurevena catalog
Research-use supplier: PRL-8-53 isn't currently listed by our research-use vendor. Their catalog carries related compounds. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Browse the catalog →

Citations (PMID)

418433

Related peptides

Arginine VasopressinA
Arginine Vasopressin: of 12,241 PubMed records, 4,072 are tagged as including female subjects and 100 carry a sex-analysis tag.
BromantaneC
Bromantane: of 62 PubMed records, 16 are tagged as including female subjects and 1 carry a sex-analysis tag.
CerebrolysinB
Cerebrolysin: of 629 PubMed records, 172 are tagged as including female subjects and 0 carry a sex-analysis tag.
DavunetideB
Davunetide: of 102 PubMed records, 24 are tagged as including female subjects and 4 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.